Trumenba, Pfizer’s meningococcal B vaccine, is now approved to be administered on a 2-dose schedule, allowing another option for providers. Trumenba can now be administered one of two ways depending on the patient’s risk profile:
- 3-dose schedule at 0, 1-2 and 6 months
- 2-dose schedule at 0 and 6 months
Please see the entire product label for complete product and safety information.